<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Vascular endothelial growth factor (VEGF) is a key upstream mediator of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, and blockade of VEGF can inhibit <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and decrease <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, not <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> respond well to anti-VEGF therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Despite much effort, identification of early response biomarkers that correlate with long-term efficacy of anti-VEGF therapy has been difficult </plain></SENT>
<SENT sid="3" pm="."><plain>These difficulties arise in part because the functional effects of VEGF inhibition on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vessels are still unclear </plain></SENT>
<SENT sid="4" pm="."><plain>We therefore assessed rapid molecular, morphologic and functional vascular responses following treatment with aflibercept (also known as VEGF Trap or ziv-aflibercept in the United States) in preclinical <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> models with a range of responses to anti-VEGF therapy, including Colo205 human colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (highly sensitive), C6 rat <z:hpo ids='HP_0100843'>glioblastoma</z:hpo> (moderately sensitive), and HT1080 human <z:hpo ids='HP_0100244'>fibrosarcoma</z:hpo> (resistant), and correlated these changes to long-term <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> inhibition </plain></SENT>
<SENT sid="5" pm="."><plain>We found that an overall decrease in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vessel perfusion, assessed by dynamic contrast-enhanced ultrasound (DCE-US), and increases in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0005039'>hypoxia</z:mp> correlated well with long-term <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> inhibition, whereas changes in vascular gene expression and microvessel density did not </plain></SENT>
<SENT sid="6" pm="."><plain>Our findings support previous clinical studies showing that decreased <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> perfusion after anti-VEGF therapy (measured by DCE-US) correlated with response </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, measuring <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> perfusion changes shortly after treatment with VEGF inhibitors, or possibly other anti-angiogenic therapies, may be useful to predict treatment efficacy </plain></SENT>
</text></document>